Inclusion criteria:
Primiparous women aged 18–45 years who are between 6 weeks and 12 months postpartum following a vaginal delivery.
A PRAFAB questionnaire score of ≥8.
Presence of at least one of the following structural or functional abnormalities on the baseline clinical assessment or magnetic resonance imaging (MRI): * Levator hiatus area >25 cm² during the Valsalva maneuver; * Levator ani muscle avulsion; * Reduced relative thickness of the puborectalis muscle compared with the contralateral side
Ability to perform a voluntary pelvic floor muscle contraction.
Willingness and ability to participate in a 6–8-week treatment program and undergo two MRI assessments.
Provision of written informed consent.
Exclusion criteria:
Subsequent pregnancy during the study period.
Cesarean delivery without an active second stage of labor (because of the different pathophysiology of levator ani muscle injury).
Severe pelvic organ prolapse (POP-Q stage ≥2) or the need for specialized conservative or surgical treatment.
Active vaginal infection, untreated bacterial vaginosis, or pelvic inflammatory disease.
History of pelvic floor disorders before pregnancy, including urinary incontinence, fecal incontinence, pelvic organ prolapse, or chronic pelvic pain.
Neuromuscular disorders affecting pelvic floor muscle contraction (e.g., multiple sclerosis, spinal cord injury, or severe peripheral neuropathy).
Presence of active electronic or metallic implants (e.g., an intrauterine device [IUD], cardiac pacemaker, or neurostimulator) that may interfere with radiofrequency treatment
Pelvic or perineal surgery within the previous 6 months.
Receipt of specialized pelvic floor treatment (e.g., supervised pelvic floor muscle training, radiofrequency therapy, or laser therapy) within the previous 3 months.
Intolerance to the vaginal radiofrequency probe.
Claustrophobia preventing MRI assessment.
Presence of active myofascial trigger points in the pelvic floor muscles on physical examination.